in the European Union, only limited action has been taken so far, whether at national or at Community level, to stimulate the development of orphan medicinal products; such action is best taken at Community level in order to take advantage of the widest possible market and to avoid the dispersion of limited resources; action at Community level is preferable to uncoordinated measures by the Member States which may result in distortions of competition and barriers to intra-Community trade;
Recital 3, Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…
In forcesince 16 Dec 1999